At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 399 enrolled
Drug / intervention
Icotinib +1 moredrug
Likely dose
Icotinib 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized,Double-blind,Multicenter Phase III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated With Chemotherapy
In Brief
A Phase 3 clinical trial evaluating Icotinib and Gefitinib for Non-small Cell Lung Cancer. Completed, enrolled 399 participants across 27 sites.
Detailed Summary
The purpose of this study is to determine whether Icotinib is at least non-inferior to Gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) patients after one or two chemotherapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedDec 2009
Primary CompletionMar 2010
Study CompletionDec 2011
TodayJul 2026
First PostedDec 30, 2009
Enrollment StartFeb 1, 2009
Primary CompletionMar 1, 2010
Study CompletionDec 1, 2011
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 16.5 years ago
Interventions
Icotinibdrug
125 mg three times daily (375 mg per day) by mouth
Gefitinibdrug
250 mg every 24 hours by mouth